TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharmas approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharmas mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXONs Spiegelmer platform has generated a proprietary pipeline of clinical-stage assets including its lead...